MELBOURNE – BioMarin Pharmaceutical Inc has agreed to acquire Amicus Therapeutics Inc in an all-cash deal valued at approximately $4.8 billion, the companies said on Monday. The acquisition includes Amicus’s commercial licensing contract for Dimerix Ltd’s experimental kidney disease therapy, DMX-200.
Under the definitive agreement, BioMarin will assume all rights and obligations from Amicus related to the licensing pact with Australian biopharmaceutical firm Dimerix. The existing agreement remains in effect, the companies stated.
Dimerix confirmed the transaction, noting its U.S. licensing deal with Amicus entitles it to receive up to $590 million in future upfront, development, and sales milestone payments, plus tiered royalties on net sales. To date, Dimerix has received $30 million from the pact, executed in May 2025.
“We are pleased to see such strong commercial interest in the rare disease space,” said Dr. Nina Webster, CEO and Managing Director of Dimerix. “BioMarin have a proven track record of navigating rare disease commercialisation.”
The acquisition is not expected to affect Dimerix’s separate licensing agreements for DMX-200 in other regions with partners including Advanz Pharma, Taiba, and Fuso. Collectively, those deals could bring Dimerix up to A$1.4 billion ($0.93 billion) in potential payments.
Dimerix’s primary focus remains the ongoing “ACTION3” Phase 3 clinical trial of DMX-200 for Focal Segmental Glomerulosclerosis (FSGS), a rare and serious kidney disorder with no specifically approved therapy in the United States.
BioMarin, a biotechnology company known for its rare disease portfolio, gains access to the DMX-200 program through the acquisition. The transaction is subject to customary closing conditions.
($1 = 1.5112 Australian dollars)